Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$2.98 USD
-0.08 (-2.61%)
Updated Sep 24, 2024 04:00 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Aprea Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -14.29 | -112.66 | -37.13 | -53.48 | -28.06 |
Depreciation/Amortization & Depletion | 0.01 | 0.19 | 0.27 | 0.23 | 0.17 |
Net Change from Assets/Liabilities | 1.62 | -1.76 | -8.33 | 5.57 | 1.16 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.48 | 89.22 | 7.50 | 5.87 | 0.02 |
Net Cash From Operating Activities | -12.18 | -25.01 | -37.69 | -41.80 | -26.71 |
Property & Equipment | -0.09 | 0.00 | 0.00 | -0.03 | -0.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.09 | 0.00 | 0.00 | -0.03 | -0.03 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 5.79 | 0.68 | 1.75 | 0.15 | 92.58 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.65 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 5.14 | 0.68 | 1.75 | 0.15 | 92.58 |
Effect of Exchange Rate Changes | -0.01 | 0.04 | 0.00 | 0.61 | -1.42 |
Net Change In Cash & Equivalents | -7.14 | -24.29 | -35.94 | -41.07 | 64.41 |
Cash at Beginning of Period | 28.79 | 53.08 | 89.02 | 130.09 | 65.68 |
Cash at End of Period | 21.65 | 28.79 | 53.08 | 89.02 | 130.09 |
Diluted Net EPS | -3.95 | -67.99 | -34.80 | -50.60 | -93.40 |
Fiscal Year End for Aprea Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -6.28 | -2.81 | -14.29 | -10.84 | -7.64 |
Depreciation/Amortization & Depletion | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | -1.47 | -1.16 | 1.62 | 2.08 | 1.20 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.16 | 0.03 | 0.48 | 0.32 | 0.24 |
Net Cash From Operating Activities | -7.58 | -3.94 | -12.18 | -8.44 | -6.20 |
Property & Equipment | -0.02 | -0.01 | -0.09 | -0.09 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.02 | -0.01 | -0.09 | -0.09 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 16.00 | 16.00 | 5.79 | 5.79 | 5.79 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.31 | -1.29 | -0.65 | -0.65 | -0.65 |
Net Cash from Financing Activities | 14.69 | 14.71 | 5.14 | 5.14 | 5.14 |
Effect of Exchange Rate Changes | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 |
Net Change In Cash & Equivalents | 7.09 | 10.76 | -7.14 | -3.39 | -1.06 |
Cash at Beginning of Period | 21.65 | 21.65 | 28.79 | 28.79 | 28.79 |
Cash at End of Period | 28.74 | 32.41 | 21.65 | 25.39 | 27.73 |
Diluted Net EPS | -0.58 | -0.67 | -0.88 | -0.86 | -0.87 |